Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05242510 · ClinicalTrials.gov registry record · NA
Evaluation of Exotropia After Patching the Eye or After Prism Adaptation
A NA study, sponsored by University of Rochester.
- Terminated
- Registry status
- NA
- Development phase
- 1
- Enrollment target
NCT05242510: Clinical Trial NA study, sponsored by University of Rochester.
NCT05242510 is a NA study that was terminated before completion, run by University of Rochester. The registered enrollment target is 1 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05242510, a NA study, was terminated before completion, sponsored by University of Rochester.
- TERMINATED
- Registry status
- NA
- Development phase
- 1 participants
- Enrollment target
Study Summary
This study intends to determine the number and percent of subjects initially diagnosed with divergence excess exotropia which would be reclassified as simulated divergence excess exotropia if tested after 24 hours of monocular occlusion (patching) or after prism adaptation for the distance angle.
Primary Outcome
Percentage of patients with distance and near exotropia measurements within 2.5 prism diopters on alternate prism and cover testing after 24 hours of patching or 7-14 days of fresnel prism use.
Interventions
- PROCEDURE Patching
- PROCEDURE Prism Adaptation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2024-08-27 |
| Est. Completion | 2024-09-18 |
| Phase | NA |
Why NCT05242510 stopped before completion
NCT05242510 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 2 interventions - of which Patching is the first listed.
NCT05242510 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05242510 about?
NCT05242510 is a clinical study titled "Evaluation of Exotropia After Patching the Eye or After Prism Adaptation". This study intends to determine the number and percent of subjects initially diagnosed with divergence excess exotropia which would be reclassified as simulated divergence excess exotropia if tested after 24 hours of monocular occlusion (patching) or after prism adaptation for the distance angle.
What is the current status of trial NCT05242510?
This trial is currently terminated. It is a NA study. The enrollment target is 1 participants. The study started on 2024-08-27. Estimated completion is 2024-09-18.
What interventions are being tested in trial NCT05242510?
The interventions under investigation include: Patching (PROCEDURE), Prism Adaptation (PROCEDURE).
Who is sponsoring clinical trial NCT05242510?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05242510's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI